---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-102170"
form_type: "8-K"
ticker: "TNYA"
cik: "0001858848"
company_name: "Tenaya Therapeutics, Inc."
filed_at: "2026-03-11T23:59:59+00:00"
generated_at: "2026-05-15T15:07:56.415572+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tenaya reports FY2025 net loss of $90.6M; cash runway into H2 2027

## Summary
- Net loss $90.6M ($0.59/share) for FY2025 vs $111.1M ($1.31) in FY2024; Q4 net loss $20.2M.
- Cash, equivalents and investments $100.5M at Dec 31, 2025; December offering net $55.8M plus Alnylam upfront extend runway into H2 2027.
- TN-201 (HCM) and TN-401 (ARVC) gene therapies: interim data presented; enrollment resumed; plans for regulatory alignment in 2026.
- Entered multi-target collaboration with Alnylam: $10M upfront, up to $1.1B milestones; Alnylam handles development and commercialization.
- TN-301 (HDAC6i) preclinical DMD data: improved grip strength to wild-type levels at 3 mg/kg, outperforming givinostat.

## SEC filing metadata
- accession: 0001193125-26-102170
- form_type: 8-K
- ticker: TNYA
- cik: 0001858848
- company_name: Tenaya Therapeutics, Inc.
- filed_at: 2026-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858848/000119312526102170/0001193125-26-102170-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858848/000119312526102170/tnya-20260311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-102170
- JSON: https://secwatch.observer/filing/0001193125-26-102170.json
- Plain text: https://secwatch.observer/filing/0001193125-26-102170.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.